EB-DT-CAR-NK

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameEB-DT-CAR-NK

Drug Alias NameAllogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 therapy (Beijing Biotech)EB-DT-CAR-NK

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsReceptor protein-tyrosine kinase erbB-2 modulatorsMucin-1 modulators +[4]

TargetsReceptor protein-tyrosine kinase erbB-2Mucin-1Inactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBeijing Biotech

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A